



CONCORDE CAPITAL

Ukraine / Coke

Avdiiivka Coke

Increasing loaded capacity

December 04, 2007

Current price: USD 3.92
12M Target: USD 6.20

BUY

Andriy Gerus

ga@concorde.com.ua

Eugene Cherviachenko

ec@concorde.com.ua

+380 44 391 5577

Tickers

Bloomberg AVDK UZ

Market information

Market price, USD	3.92
MCap, USD mln	759.8
52Wk Hi/Low, USD	4.41/1.68
No of shares, mln	193.6
Free float	3.2%
Free float, USD mln	24.3

Corporate Governance

Concorde Rating* P

* The rating is based on Concorde Capital's corporate governance survey. Q denotes quality corporate governance standards, AA - above average standards, A - average, BA - below average and P - poor.

Shareholders

Metinvest	90.9%
MMK Illich Steel	5.9%
Other	3.2%

Ratios 2007E

EBITDA margin	8.5%
Net margin	-8.5%
Net debt/equity	0.14

- The company's plan to commence production at two more coke batteries in the next two years supports our long-term forecast of output growth at 6.7% 5Y CAGR
- 9M sales and EBITDA were in line with our expectations; net income dropped apparently due to one-off non-cash losses from the transfer of its stake in Pavlohrad Coal
- Target price unchanged

Production forecasts supported

Our forecasts of Avdiivka boosting production to 4.7 mln mt per annum in 2012, or 48% more than its level in 2006 (see our October 18 report) was substantiated by yesterday's news in trade publication Metal Courier:

- Avdiivka Coke plans to launch coke battery #3, currently in standby mode, to meet additional demand. The battery is expected to reach full capacity (690 ths mt annually) by mid-2008
- The company will also overhaul coke battery #4 to double the oven's capacity to 690 ths mt annually. It expects to launch the battery in 2009

9M07 sales, EBITDA as expected, net income distorted

- Sales grew 27.2% yoy to USD 581.3 mln (vs. our 2007 forecast of 28.5% yoy), EBITDA margin was 8.3% (close to our full year forecast of 8.5%)
- Net income dropped in 3Q07 due to 'other expenses' of USD 61.7 mln, which we attribute to one-off non-cash losses. In August 2007 Avdiivka transferred its 92.1% stake in Pavlohrad Coal to DTEK, SCM's energy wing, apparently at a lower price than paid at privatization in 2004
- Normalized net income in 3Q07 amounted USD 0.7 mln vs USD -8.7 mln in 2Q07. We expect normalized net income of USD 10 mln in 3Q07 and negative USD 2.6 mln in 2007, less than our previous 2007 projection of USD 9.1 mln due to higher D&A and interest expenses. We forecast a reported net loss of USD 70.6 mln in 2007
- We update our 2007 forecasts, and maintain our long-term projections

	2Q07	3Q07	QoQ	9M06	9M07	YoY	new 2007E	old 2007E
Sales	214.4	203.0	-5.3%	457.0	581.3	27.2%	830.0	830.0
EBITDA	11.1	26.6	139.5%	61.4	48.0	-21.9%	70.7	70.7
margin, %	5.2%	13.1%	7.9p.p.	13.4%	8.3%	-5.1 p.p.	8.5%	8.5%
Net income	-8.7	-60.9	n/m	16.8	-80.6	n/m	-70.6	9.1
margin, %	-4.0%	-30.0%	-26.0p.p.	3.7%	-13.9%	-17.6 p.p.	-8.5%	1.1%

Recent correction revealed more upside


- During November's market correction, AVDK's price dropped 11% from USD 4.41 per share to USD 3.92
- We reiterate 12M target price of USD 6.20 (58% upside). We maintain BUY

Stock performance, 12M*




Source: PFTS, Bloomberg. * PFTS index, SCM BGI rebased to AVDK's price

Sector Performance, YTD



PFTS Trading Volumes, USD ths



Key financials & ratios, USD mln

	Revenue	EBITDA margin	Net margin	EV/S	EV/EBITDA	P/E
2006	647.7	12.3%	1.6%	1.4	11.4	73.1
2007E	832.2	8.5%	-8.5%	1.1	12.7	n/m
2008E	930.8	13.5%	6.0%	0.9	7.0	13.7

Spot exchange rate: 5.05 UAH/USD

Quarterly Financial Statements

Income statement summary, USD mln

	1Q05	2Q05	3Q05	4Q05	1Q06	2Q06	3Q06	4Q06	1Q07	2Q07	3Q07
Net Revenues	458.4	272.3	178.5	210.6	116.6	170.1	170.3	190.7	163.8	214.4	203.0
Cost Of Sales	(378.0)	(225.0)	(148.8)	(178.9)	(94.7)	(143.0)	(134.6)	(168.2)	(147.3)	(194.8)	(169.2)
Gross Profit	80.4	47.4	29.7	31.7	21.9	27.1	35.8	22.4	16.5	19.6	33.8
<i>Gross margin</i>	<i>17.5%</i>	<i>17.4%</i>	<i>16.7%</i>	<i>15.1%</i>	<i>18.8%</i>	<i>15.9%</i>	<i>21.0%</i>	<i>11.8%</i>	<i>10.1%</i>	<i>9.2%</i>	<i>16.7%</i>
Other Operating Income/Costs, net	(0.8)	(1.1)	16.4	8.4	(1.0)	(5.4)	(1.0)	1.2	(1.2)	(3.1)	(2.1)
SG&A	(4.5)	(6.5)	(4.3)	(7.8)	(5.0)	(6.0)	(4.9)	(5.4)	(5.1)	(5.4)	(5.2)
EBITDA	75.1	39.8	41.8	32.3	16.0	15.6	29.8	18.3	10.3	11.1	26.6
<i>EBITDA margin</i>	<i>16.4%</i>	<i>14.6%</i>	<i>23.4%</i>	<i>15.3%</i>	<i>13.7%</i>	<i>9.2%</i>	<i>17.5%</i>	<i>9.6%</i>	<i>6.3%</i>	<i>5.2%</i>	<i>13.1%</i>
Depreciation	(4.1)	(4.2)	(4.3)	(4.3)	(4.1)	(4.2)	(4.3)	(4.6)	(13.9)	(14.7)	(15.3)
EBIT	70.9	35.6	37.5	27.9	11.9	11.5	25.6	13.7	(3.6)	(3.6)	11.3
<i>EBIT margin</i>	<i>15.5%</i>	<i>13.1%</i>	<i>21.0%</i>	<i>13.3%</i>	<i>10.2%</i>	<i>6.7%</i>	<i>15.0%</i>	<i>7.2%</i>	<i>-2.2%</i>	<i>-1.7%</i>	<i>5.6%</i>
Interest Expense	(12.4)	(12.0)	(12.5)	(12.4)	(7.5)	(5.8)	(4.8)	(3.6)	(3.6)	(3.1)	(4.0)
Financial income/(expense)	-	0.0	-	(32.2)	-	-	-	(9.4)	0.0	0.0	0.0
Other income/(expense)	2.8	21.3	0.7	0.1	(1.1)	0.4	(3.2)	(3.6)	0.3	1.1	(61.7)
PBT	61.3	44.9	25.8	(16.6)	3.3	6.0	17.6	(2.8)	(7.0)	(5.6)	(54.4)
Tax	(14.7)	(12.6)	(4.7)	(11.3)	(2.0)	(3.5)	(4.3)	(3.6)	(4.0)	(3.1)	(6.5)
Net Income	46.6	32.5	21.3	(28.0)	1.1	2.4	13.2	(6.4)	(11.0)	(8.7)	(60.9)
<i>Net Margin</i>	<i>10.2%</i>	<i>11.9%</i>	<i>11.9%</i>	<i>-13.3%</i>	<i>1.0%</i>	<i>1.4%</i>	<i>7.8%</i>	<i>-3.4%</i>	<i>-6.7%</i>	<i>-4.0%</i>	<i>-30.0%</i>

Balance sheet summary, USD mln

	1Q05	2Q05	3Q05	4Q05	1Q06	2Q06	3Q06	4Q06	1Q06	2Q07	3Q07
Current Assets	349.5	230.1	167.7	200.3	231.5	163.8	164.4	162.7	303.8	220.3	581.4
Cash & Equivalents	13.8	6.5	10.1	36.1	13.1	8.8	3.2	3.7	2.8	2.1	3.5
Trade Receivables	117.5	113.2	89.3	46.3	40.0	52.2	69.1	31.0	130.1	53.6	128.4
Inventories	38.1	54.8	33.6	35.1	35.4	31.2	31.6	44.2	43.4	41.4	39.9
Other current assets	180.0	55.5	34.7	82.7	143.1	71.5	60.5	83.8	127.4	123.2	409.6
Fixed Assets	954.1	1,095.0	1,098.7	844.1	789.3	791.8	780.2	1,177.7	1,126.3	1,111.4	760.8
PP&E, net	129.3	134.2	133.4	134.6	131.1	137.6	135.3	434.6	428.0	417.2	408.3
Other Fixed Assets	824.8	960.9	965.3	709.5	658.2	654.2	644.9	743.1	698.3	694.2	352.5
Total Assets	1,303.6	1,325.1	1,266.3	1,044.3	1,020.8	955.6	944.6	1,340.4	1,430.1	1,331.7	1,342.2
Shareholders' Equity	519.6	575.5	597.4	578.8	580.0	582.4	594.9	846.5	840.7	834.5	773.4
Share Capital	64.5	67.4	67.5	67.5	67.5	67.5	67.5	67.5	67.5	67.5	67.5
Reserves and Other	107.1	111.8	111.9	122.3	122.2	122.0	121.5	341.9	332.6	322.9	290.3
Retained Earnings	348.0	396.3	418.1	389.0	390.4	392.9	405.9	437.1	440.5	444.1	415.6
Current Liabilities	278.0	245.9	172.5	144.3	239.3	342.1	193.2	252.2	349.4	309.8	404.6
ST Interest Bearing Debt	-	-	-	-	108.9	205.0	24.5	-	-	-	-
Trade Payables	169.1	141.7	73.1	94.3	55.8	60.5	51.9	140.4	237.5	203.8	273.0
Accrued Wages	1.0	1.1	1.1	1.2	1.2	1.2	1.2	1.2	1.3	1.3	1.5
Accrued Taxes	14.6	10.0	2.1	0.4	0.5	0.4	0.4	0.4	0.5	0.5	6.7
Other Current Liabilities	93.3	93.1	96.3	48.4	73.0	75.0	115.2	110.2	110.1	104.3	123.3
LT Liabilities	506.0	503.7	496.4	321.2	201.5	31.0	156.5	241.7	240.1	187.4	164.2
LT Interest Bearing Debt	479.0	472.1	472.1	297.7	177.9	7.5	133.0	150.0	150.0	99.6	100.0
Other LT	27.0	31.5	24.3	23.6	23.6	23.6	23.6	91.7	90.1	87.8	64.2
Total Liabilities & Equity	1,303.6	1,325.1	1,266.3	1,044.3	1,020.8	955.6	944.6	1,340.4	1,430.1	1,331.7	1,342.2

Projected Financials

Income statement summary, USD mln

	2005	2006	2007E	2008E	2009E	2010E	2011E	2012E
Net Revenues	1,128	648	830.0	928	996	1,053	1,145	1,168
<i>Change, yoy</i>	<i>N/M</i>	<i>-42.6%</i>	<i>28.1%</i>	<i>11.8%</i>	<i>7.3%</i>	<i>5.7%</i>	<i>8.8%</i>	<i>2.1%</i>
Cost Of Sales	(938)	(540)	(735)	(770)	(822)	(868)	(944)	(964)
Gross Profit	191	107	95	158	174	184	200	204
Other Operating Income/Costs, net	23	(6)	-	-	-	-	-	-
SG&A	(23)	(21)	(25)	(32)	(35)	(37)	(40)	(41)
EBITDA	190	80	71	125	139	147	160	164
<i>EBITDA margin</i>	<i>16.9%</i>	<i>12.3%</i>	<i>8.5%</i>	<i>13.5%</i>	<i>14.0%</i>	<i>14.0%</i>	<i>14.0%</i>	<i>14.0%</i>
Depreciation	(17)	(17)	(35)	(35)	(35)	(35)	(35)	(35)
EBIT	173	63	36	91	105	113	125	129
<i>EBIT margin</i>	<i>15.4%</i>	<i>9.7%</i>	<i>4.3%</i>	<i>9.8%</i>	<i>10.5%</i>	<i>10.7%</i>	<i>11.0%</i>	<i>11.0%</i>
Interest Expense	(49)	(22)	(24)	(17)	(15)	(13)	(11)	(10)
Financial income/(expense)	(32)	(9)	-	-	-	-	-	-
Other income/(expense)	25	(8)	(60.3)	-	-	-	-	-
PBT	117	24	(53.7)	74	90	100	114	118
Tax	(44)	(13)	(17)	(19)	(23)	(25)	(29)	(30)
Net Income	74	10	(70.6)	56	68	75	86	89
<i>Net Margin</i>	<i>6.6%</i>	<i>1.6%</i>	<i>-8.5%</i>	<i>6.0%</i>	<i>6.8%</i>	<i>7.1%</i>	<i>7.5%</i>	<i>7.6%</i>

Balance sheet summary, USD mln

	2005	2006	2007E	2008E	2009E	2010E	2011E	2012E
Current Assets	200	163	174	193	206	214	222	220
Cash & Equivalents	36	4	5	6	6	6	7	7
Trade Receivables	46	31	74	84	90	95	103	105
Inventories	35	44	37	39	41	43	42	39
Other current assets	83	84	58	65	70	70	70	70
Fixed Assets	844	1,178	900	899	899	900	899	899
PP&E, net	135	435	468	467	467	467	467	467
Other Fixed Assets	710	743	432	432	432	432	432	432
Total Assets	1,044	1,340	1,074	1,092	1,106	1,114	1,121	1,120
Shareholders' Equity	579	846	785	821	841	863	881	898
Share Capital	67	67	67	67	67	67	67	67
Reserves and Other	511	779	718	754	774	797	814	831
Retained Earnings	144	252	119	126	132	137	147	150
Current Liabilities	-	-	12	14	12	11	11	12
ST Interest Bearing Debt	94	140	80	83	89	94	99	101
Trade Payables	1	1	1	1	1	1	1	1
Accrued Wages	0	0	0	0	0	0	0	0
Accrued Taxes	48	110	25	28	30	32	34	35
Other Current Liabilities	321	242	127	108	92	75	59	59
LT Liabilities	298	150	127	108	92	75	59	59
LT Interest Bearing Debt	24	92	-	-	-	-	-	-
Other LT	1,044	1,340	1,074	1,092	1,106	1,114	1,121	1,120
Total Liabilities & Equity	579	846	785	821	841	863	881	898

Appendix - Disclosures

Analyst Certification

We, Andriy Gerus and Eugene Cherviachenko, hereby certify that the views expressed in this research report accurately reflect our personal views about the subject securities and issuers. We also certify that no part of our compensation was, is, or will be, directly or indirectly, related to the specific recommendations or views expressed in this research report.

Avdiyivka Coke

Date	Target price, USD	Market Price, USD	Rec'	Action
23-Sept-05	6.74	3.56	BUY	Initiating
23-Aug-06	4.79	2.96	BUY	Upgrade
29-Dec-06	4.79	2.00	BUY	Maintain
28-Feb-07	5.14	2.13	BUY	Maintain
17-Oct-07	6.20	3.08	BUY	Maintain
04-Dec-07	6.20	3.92	BUY	Maintain

* Until March 2007 the company was covered by Andriy Gostik, who now focuses on another sector. In February 2007, Eugene Cherviachenko took over coverage; in October 2007, he was joined by Andriy Gerus.

AVDK Recommendation history, USD per share



Investment Ratings

The time horizon for target prices in Concorde Capital's research is 12 months unless otherwise stated. Concorde Capital employs three basic investment ratings: Buy, Hold and Sell. Typically, Buy recommendation is associated with an upside of 15% or more from the current market price; Sell is prompted by downside from the current market price (upside <0%); Hold recommendation is generally for limited upside within 15%. Though investment ratings are generally induced by the magnitude of upside, they are not derived on this basis alone. In certain cases, an analyst may have reasons to establish a recommendation where the associated range given above does not correspond. Temporary discrepancies between an investment rating and its upside at a specific point in time due to price movement and/or volatility will be permitted; Concorde Capital may revise an investment rating at its discretion. A recommendation and/or target price might be placed Under Review when impelled by corporate events, changes in finances or operations. Investors should base decisions to Buy, Hold or Sell a stock on the complete information regarding the analyst's views in the research report and on their individual investment objectives and circumstances.

Concorde Capital ratings distribution

Buy	37	44%
Hold	29	35%
Sell	7	8%
Under Review	11	13%
Total	84	100%

Investment banking clients*

Buy	8	80%
Hold	2	20%
Sell	0	0%
Under Review	0	0%
Total	10	100%

* Concorde Capital provided investment banking services to the company within the past 12 months.

Concorde Capital
2 Mechnikova Street
21st Floor
Kyiv 01601, UKRAINE

Tel.: +380 44 391 5577
Fax: +380 44 391 5571
www.concorde.com.ua
office@concorde.com.ua

CEO

Igor Mazepa

im@concorde.com.ua

Equity Sales

Anastasiya Nazarenko
 Zack Watson
 Duff Kovacs, CFA
 Marina Martirosyan

an@concorde.com.ua
 zw@concorde.com.ua
 dk@concorde.com.ua
 mm@concorde.com.ua

Director of Research

Konstantin Fisun, CFA

kf@concorde.com.ua

RESEARCH COVERAGE BY SECTOR

Strategy

Konstantin Fisun
 Oleksandr Klymchuk

kf@concorde.com.ua
 ok@concorde.com.ua

Metals & Mining

Eugene Cherviachenko
 Andriy Gerus

ec@concorde.com.ua
 ga@concorde.com.ua

Utilities (Telecom, Energy)

Alexander Paraschiy

ap@concorde.com.ua

Oil & Gas, Chemicals

Vladimir Nesterenko

vn@concorde.com.ua

Consumer/Real Estate Group

Andriy Gostik, CFA
 Olha Pankiv
 Alexander Romanov
 Anna Dudchenko

ag@concorde.com.ua
 op@concorde.com.ua
 ar@concorde.com.ua
 ad@concorde.com.ua

Machinery

Eugene Cherviachenko
 Inna Perepelytsya

ec@concorde.com.ua
 pi@concorde.com.ua

Financial Services, Retail

Alexander Viktorov

av@concorde.com.ua

Macroeconomics

Polina Khomenko

pk@concorde.com.ua

Fixed Income

Oleksandr Klymchuk

ok@concorde.com.ua

Corporate Governance

Nick Piazza

np@concorde.com.ua

News/Production

Nick Piazza
 Polina Khomenko

np@concorde.com.ua
 pk@concorde.com.ua

Editor

Brad Wells

bw@concorde.com.ua

Disclaimer

This report has been prepared by Concorde Capital investment bank for informational purposes only. Concorde Capital does and seeks to do business with companies covered in its research reports. As a result, investors should be aware that Concorde Capital might have a conflict of interest that could affect the objectivity of this report.

Concorde Capital, its directors and employees or clients might have or have had interests or long /short positions in the securities referred to herein, and might at any time make purchases and/or sales in them as a principal or an agent. Concorde Capital might act or has acted as a market-maker in the securities discussed in this report. The research analysts and/or corporate banking associates principally responsible for the preparation of this report receive compensation based upon various factors, including quality of research, investor/client feedback, stock picking, competitive factors, firm revenues and investment banking revenues.

Prices of listed securities referred to in this report are denoted in the currency of the respective exchanges. Investors in financial instruments such as depository receipts, the values or prices of which are influenced by currency volatility, effectively assume currency risk.

Due to the timely nature of this report, the information contained might not have been verified and is based on the opinion of the analyst. We do not purport this document to be entirely accurate and do not guarantee it to be a complete statement or summary of available data. Any opinions expressed herein are statements of our judgments as of the date of publication and are subject to change without notice. Reproduction without prior permission is prohibited. © 2007 Concorde Capital